Impact on guidelines: The general practitioner point of view

被引:5
|
作者
Cos, X. [1 ]
Seidu, S. [2 ]
Brunton, S. [3 ]
Harris, S. B. [4 ]
Jansson, S. P. O. [5 ]
Mata-Cases, M. [6 ]
Neijens, A. M. J. [7 ]
Topsever, P. [8 ]
Khunti, K. [2 ]
机构
[1] Univ Res Inst Primary Care IDIAP Jordi Gol, Inst Catala Salut, St Marti Provencals Primary Care Ctr, Barcelona, Spain
[2] Univ Leicester, Leicester Gen Hosp, Diabet Res Ctr, Gwendolen Rd, Leicester LE5 4PW, Leics, England
[3] Primary Care Metab Grp, Los Angeles, CA USA
[4] Western Univ, Schulich Sch Med & Dent, Dept Family Med, London, ON, Canada
[5] Orebro Univ, Univ Hlth Care Res Ctr, Sch Med Sci, Orebro, Sweden
[6] Inst Salud Carlos III ISCIII, Univ Res Inst Primary Care IDIAP Jordi Gol, Inst Catala Salut, La Mina Primary Care Ctr,CIBER Diabet & Associate, Barcelona, Spain
[7] QOL Consultancy, Nurse Led Case Management Diabet, Deventer, Netherlands
[8] Acibadem Mehmet Ali Aydinlar Univ, Dept Family Med, Sch Med, Kerem Aydinlar Campus, TR-34752 Istanbul, Turkey
关键词
Type; 2; diabetes; Cardiovascular disease; Cardiovascular risk factors; Therapeutic inertia; Heart failure; Primary care; Chronic kidney disease; CARDIOVASCULAR OUTCOMES TRIALS; GLYCEMIC CONTROL; GLUCOSE CONTROL; PRIMARY-CARE; TYPE-2; EMPAGLIFLOZIN; COMPLICATIONS; HYPERGLYCEMIA; EXENATIDE; METFORMIN;
D O I
10.1016/j.diabres.2020.108091
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary care physicians are uniquely placed to offer holistic, patient-centred care to patients with T2DM. While the recent FDA-mandated cardiovascular outcome trials offer a wealth of data to inform treatment discussions, they have also contributed to increasing complexity in treatment decisions, and in the guidelines that seek to assist in making these decisions. To assist physicians in avoiding treatment inertia, Primary Care Diabetes Europe has formulated a position statement that summarises our current understanding of the available T2DM treatment options in various patient populations. New data from recent outcomes trials is contextualised and summarised for the primary care physician. This consensus paper also proposes a unique and simple tool to stratify patients into 'very high' and 'high' cardiovascular risk categories and outlines treatment recommendations for patients with atherosclerotic cardiovascular disease, heart failure and chronic kidney disease. Special consideration is given to elderly/frail patients and those with obesity. A visual patient assessment tool is provided, and a comprehensive set of prescribing tips is presented for all available classes of glucose-lowering therapies. This position statement will complement the already available, often specialist-focused, T2DM treatment guidelines and provide greater direction in how the wealth of outcome trial data can be applied to everyday practice. (C) 2020 Published by Elsevier B.V.
引用
收藏
页数:9
相关论文
共 50 条